1ob3

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: 200px<br /><applet load="1ob3" size="450" color="white" frame="true" align="right" spinBox="true" caption="1ob3, resolution 1.90&Aring;" /> '''STRUCTURE OF P. FALC...)
Line 1: Line 1:
-
[[Image:1ob3.jpg|left|200px]]<br /><applet load="1ob3" size="450" color="white" frame="true" align="right" spinBox="true"
+
[[Image:1ob3.jpg|left|200px]]<br /><applet load="1ob3" size="350" color="white" frame="true" align="right" spinBox="true"
caption="1ob3, resolution 1.90&Aring;" />
caption="1ob3, resolution 1.90&Aring;" />
'''STRUCTURE OF P. FALCIPARUM PFPK5'''<br />
'''STRUCTURE OF P. FALCIPARUM PFPK5'''<br />
==Overview==
==Overview==
-
Plasmodium falciparum cell cycle regulators are promising targets for, antimalarial drug design. We have determined the structure of PfPK5, the, first structure of a P. falciparum protein kinase and the first of a, cyclin-dependent kinase (CDK) not derived from humans. The fold and the, mechanism of inactivation of monomeric CDKs are highly conserved across, evolution. ATP-competitive CDK inhibitors have been developed as potential, leads for cancer therapeutics. These studies have identified regions of, the CDK active site that can be exploited to achieve significant gains in, inhibitor potency and selectivity. We have cocrystallized PfPK5 with three, inhibitors that target such regions. The sequence differences between, PfPK5 and human CDKs within these inhibitor binding sites suggest that, selective inhibition is an attainable goal. Such compounds will be useful, tools for P. falciparum cell cycle studies, and will provide lead, compounds for antimalarial drug development.
+
Plasmodium falciparum cell cycle regulators are promising targets for antimalarial drug design. We have determined the structure of PfPK5, the first structure of a P. falciparum protein kinase and the first of a cyclin-dependent kinase (CDK) not derived from humans. The fold and the mechanism of inactivation of monomeric CDKs are highly conserved across evolution. ATP-competitive CDK inhibitors have been developed as potential leads for cancer therapeutics. These studies have identified regions of the CDK active site that can be exploited to achieve significant gains in inhibitor potency and selectivity. We have cocrystallized PfPK5 with three inhibitors that target such regions. The sequence differences between PfPK5 and human CDKs within these inhibitor binding sites suggest that selective inhibition is an attainable goal. Such compounds will be useful tools for P. falciparum cell cycle studies, and will provide lead compounds for antimalarial drug development.
==About this Structure==
==About this Structure==
-
1OB3 is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Plasmodium_falciparum Plasmodium falciparum]. Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1OB3 OCA].
+
1OB3 is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Plasmodium_falciparum Plasmodium falciparum]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1OB3 OCA].
==Reference==
==Reference==
Line 25: Line 25:
[[Category: transferase]]
[[Category: transferase]]
-
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Tue Nov 20 22:53:49 2007''
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 14:15:35 2008''

Revision as of 12:15, 21 February 2008


1ob3, resolution 1.90Å

Drag the structure with the mouse to rotate

STRUCTURE OF P. FALCIPARUM PFPK5

Overview

Plasmodium falciparum cell cycle regulators are promising targets for antimalarial drug design. We have determined the structure of PfPK5, the first structure of a P. falciparum protein kinase and the first of a cyclin-dependent kinase (CDK) not derived from humans. The fold and the mechanism of inactivation of monomeric CDKs are highly conserved across evolution. ATP-competitive CDK inhibitors have been developed as potential leads for cancer therapeutics. These studies have identified regions of the CDK active site that can be exploited to achieve significant gains in inhibitor potency and selectivity. We have cocrystallized PfPK5 with three inhibitors that target such regions. The sequence differences between PfPK5 and human CDKs within these inhibitor binding sites suggest that selective inhibition is an attainable goal. Such compounds will be useful tools for P. falciparum cell cycle studies, and will provide lead compounds for antimalarial drug development.

About this Structure

1OB3 is a Single protein structure of sequence from Plasmodium falciparum. Full crystallographic information is available from OCA.

Reference

Structures of P. falciparum PfPK5 test the CDK regulation paradigm and suggest mechanisms of small molecule inhibition., Holton S, Merckx A, Burgess D, Doerig C, Noble M, Endicott J, Structure. 2003 Nov;11(11):1329-37. PMID:14604523

Page seeded by OCA on Thu Feb 21 14:15:35 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools